Octreotide in Treating Patients With Cancer-Related Malignant Ascites

Completed · Phase 3 · Has a placebo group

Conditions studied: Metastatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific

In brief

RATIONALE: Octreotide may be an effective treatment for malignant ascites. It is not yet known whether octreotide is more effective than a placebo in treating malignant ascites. PURPOSE: This randomized phase III trial is studying octreotide to see how well it works compared to placebo in treating patients with cancer-related malignant ascites.

Key facts

Study ID
NCT00182754
Run by
Alliance for Clinical Trials in Oncology
People needed
33
Starts
2005-10-01
Expected to finish
2013-03-01
Last updated by the study team
2017-04-11

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.